VY-3-135
规格
| Cas Number | 1824637-41-3 |
| 规格或纯度 | ≥98% |
| 纯度 | ≥98% |
| 包装 | 50mg 或 10mg 或 1mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 50 mg/mL (116.41 mM; Need ultrasonic) |
| 储存温度 | 避光,-80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | VY-3-135 是一种强效、具有口服活性且稳定的 ACSS2 抑制剂，其 IC 50 值为 44 nM。VY-3-135 对 AcCoA 合成酶家族中的 ACSS2 具有特异性。VY-3-135 不会抑制 ACSS1 或 ACSS3 的酶活性。VY-3-135 可用于 |
| 英文描述 |
VY-3-135 is a potent, orally active, and stable ACSS2 inhibitor with an IC 50 value of 44 nM. VY-3-135 is specific to ACSS2 among the AcCoA synthetase family of enzymes. VY-3-135 does not inhibit ACSS1 or ACSS3 enzymatic activity. VY-3-135 can be used for the research of breast cancer. In Vitro VY-3-135 (0.1, 1 μM; for 24 hours) blocks acetate dependent labeling of palmitate by 13C2-acetate in ACSS2 low A7C11 and ACSS2 high Brpkp110 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo VY-3-135 (100 mg/kg/day; PO; 30 days) represses MDA-MB-468 (ACSS2 high ) tumor growth but is mostly ineffective at blocking WHIM12 (ACSS2 low ) growth . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |